Outcome of exudative aged-related macular degeneration (ARMD) after 3 intravitreal injections of bevacizumab
| Autor: | Am Bron, Ml Bidot, C Creuzot, M. Souchier, L. Malvitte |
|---|---|
| Přispěvatelé: | FLAveur, VIsion et Comportement du consommateur (FLAVIC), Etablissement National d'Enseignement Supérieur Agronomique de Dijon (ENESAD)-Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Université de Bourgogne (UB) |
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
Bevacizumab genetic structures Therapy naive 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Ophthalmology medicine Residual activity [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs medicine.diagnostic_test business.industry Retrospective cohort study Retinal General Medicine Macular degeneration medicine.disease eye diseases Surgery chemistry Angiography 030221 ophthalmology & optometry business Complication 030217 neurology & neurosurgery [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology medicine.drug |
| Zdroj: | Acta Ophthalmologica European Association for Vision and Eye Research (EVER) annual congress European Association for Vision and Eye Research (EVER) annual congress, 2009, ⟨10.1111/j.1755-3768.2009.3312.x⟩ |
| DOI: | 10.1111/j.1755-3768.2009.3312.x⟩ |
| Popis: | Purpose To evaluate the efficacy of intravitreal injections of bevacizumab in exudative ARMD. Methods Retrospective study including naive patients suffering from exudative ARMD whatever the type of neovascularisation. All the participants were treated with three monthly 1.25 mg intravitreal injections of bevacizumab.The primary objective was far and near visual acuity (VA) 1, 3 and 6 months after the third injection. The secondary objective was the residual activity of neovascularisation assessed with fluorescein and ICG angiography and retinal thickness evaluated with OCT3. Results 71 eyes of 66 patients were included. Neovascularisation was occult, visible or combined in 65%, 20% and 15% of the cases, respectively. A statistically significant improvement between pre and post-injection VA (LogMAR) was observed one month after the third injection, 0.88±0.57 and 0.77±0.60, respectively, p=0.001). An active neovascularisation was still present at that time in 57.7% of the eyes and 34% at 6 months needing further bevacizumab injections (3.85±0.96 per eye). VA was similar at 1, 3 and 6 months (F71,2=1,54 ; p=0,46). A complication occurred in 3 eyes. Conclusion Three bevacizumab intravitreal injections led to a significant VA improvement. However, more than half of the eyes had an active neovascularisation after these 3 injections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|